Newsylist real-time news trend intelligence
▲ Peaking Business

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

Vertex Pharmaceuticals is acquiring commercial endocrinology biotech Crinetics Pharmaceuticals in a $10 billion deal.

5sources
5articles
3velocity
+0%since first seen
13m agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 7 06:29Jul 7 08:29 UTC

The brief

Vertex Pharmaceuticals has reached an agreement to acquire Crinetics Pharmaceuticals for $10 billion. This acquisition marks the largest deal to date for Vertex.

Coverage from Bloomberg, The Wall Street Journal, and STAT emphasizes that the deal occurs amid a broader boom in biotech mergers and acquisitions. Following the announcement, Yahoo Finance reports that CRNX stock rose nearly 100% in after-hours trading.

Future developments will depend on the completion of the acquisition process as Vertex integrates the commercial endocrinology firm into its operations.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 9m ago.

Quick answers

How much is Vertex paying for Crinetics Pharmaceuticals?

The deal is valued at $10 billion.

How did the market react to the news?

According to Yahoo Finance, CRNX stock soared nearly 100% after-hours.

What is Crinetics Pharmaceuticals' area of specialization?

Crinetics is described as a commercial endocrinology biotech.

Coverage (5)

People, places & organizations

Topics

Related trends